AI-generated summary
In two linked studies, the authors tested photobiomodulation therapy on the tibialis anterior muscle of ambulatory people with multiple sclerosis, comparing active treatment with placebo. They report that a high dose improved force recovery in the first study, and that two weeks of individualized active treatment improved muscle strength compared with placebo. Endurance time and muscle fatigue did not significantly improve, and the authors suggest the findings are preliminary.
- Participants
- 17
- Who or what was studied
- Ambulatory adults with multiple sclerosis (mild-moderate MS); study I N = 17 and study II N = 12, a subgroup of study I
- Wavelengths
- 600, 1100 nm
- Limits stated in the abstract
- Small sample sizes in both studies, and the abstract describes the bandwidth and conclusions as suggestive rather than definitive.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 600-1100 nm
- Total energy
- 40 J, 80 J, 120 J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Dose, Low-level laser therapy, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.